These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 11051239)

  • 1. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.
    Alsner J; Yilmaz M; Guldberg P; Hansen LL; Overgaard J
    Clin Cancer Res; 2000 Oct; 6(10):3923-31. PubMed ID: 11051239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
    Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
    Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
    Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
    Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
    Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
    Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay.
    Chappuis PO; Estreicher A; Dieterich B; Bonnefoi H; Otter M; Sappino AP; Iggo R
    Int J Cancer; 1999 Dec; 84(6):587-93. PubMed ID: 10567903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
    Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
    Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.
    Végran F; Rebucci M; Chevrier S; Cadouot M; Boidot R; Lizard-Nacol S
    PLoS One; 2013; 8(1):e55103. PubMed ID: 23359294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
    van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
    J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Mutation and Expression of
    Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.